作为山东未名生物医药股份有限公司（以下简称"公司"）的独立董事，本人严格 按照《公司法》《上市公司独立董事管理办法》《上市公司治理准则》《公司章程》等 相关法律法规和规章制度的规定和要求，诚信、勤勉、独立地履行独立董事职责，积极 出席相关会议，认真审议各项议案，促进公司规范运作，切实维护全体股东尤其是中小 股东的合法权益。现将2024年度履职情况报告如下： 山东未名生物医药股份有限公司 2024年度独立董事述职报告（夏阳） 本人夏阳，男，61岁，中国国籍，现任于北京华达杰瑞生物技术有限公司董事长职 务，曾任于天津药物研究院，深圳海王药业有限公司经理，武汉人福科技股份有限公司 医药公司总经理，北京紫华康泰医药公司（现更名为北京博智创盛医药有限公司）副总 裁、总经理，Frost & Sullivan中国区医药副总裁。2022年8月至今任公司独立董事。 本人作为公司的独立董事，符合《上市公司独立董事管理办法》规定的独立性要 求和任职条件，没有在公司担任除独立董事以外的其他任何职务，没有从公司及其主 要股东或有利害关系的机构和人员处取得额外的、未予披露的其他利益，不存在影响 上市公司独立性和独立董事独立性的情况。 一 ...

Financial Performance - The company's operating revenue for 2024 was ¥360,405,014.10, a decrease of 16.14% compared to ¥429,790,105.06 in 2023[19]. - The net loss attributable to shareholders for 2024 was ¥137,313,572.01, an improvement of 58.70% from a loss of ¥332,458,291.49 in 2023[18]. - The net profit after deducting non-recurring gains and losses was ¥-111,071,714.23 for 2024, showing a 65.02% improvement from ¥-317,565,023.48 in 2023[18]. - The cash flow from operating activities for 2024 was ¥-6,547,055.74, an 82.07% improvement compared to ¥-36,506,204.20 in 2023[18]. - The basic earnings per share for 2024 was ¥-0.2081, improving by 58.70% from ¥-0.5039 in 2023[18]. - Total assets at the end of 2024 were ¥2,195,918,588.20, a decrease of 6.04% from ¥2,337,137,949.03 at the end of 2023[18]. - The net assets attributable to shareholders at the end of 2024 were ¥1,923,634,393.24, down 7.00% from ¥2,068,467,729.91 at the end of 2023[18]. - The company reported a quarterly revenue of ¥45,694,750.58 in Q4 2024, significantly lower than Q3's ¥103,928,259.06[23]. - The company experienced a net loss of ¥151,939,840.31 in Q4 2024, following a profit of ¥44,241,185.37 in Q3[23]. Shareholder Information - The company reported a profit distribution plan based on a base of 659,735,586 shares, with a cash dividend of 0 per 10 shares and no bonus shares issued[5]. - The company has a commitment to transparency, with all board members present for the report's approval[4]. - The company's financial report is available for public access on the Shenzhen Stock Exchange website and other designated media[15]. - The company held its first temporary shareholders' meeting on January 16, 2024, with an investor participation rate of 28.51%[87]. - The annual shareholders' meeting took place on May 22, 2024, with a participation rate of 28.85%[87]. - The second temporary shareholders' meeting was held on October 24, 2024, with a participation rate of 28.96%[88]. - The third temporary shareholders' meeting is scheduled for November 15, 2024, with a participation rate of 28.52%[88]. - The fourth temporary shareholders' meeting will be on December 18, 2024, with a participation rate of 21.11%[88]. Corporate Governance - The company maintains complete independence from its controlling shareholder in business, personnel, assets, institutions, and finance[85]. - The company has established an independent financial planning center with dedicated financial personnel, ensuring compliance with accounting standards and independent tax obligations[86]. - The company has a transparent performance evaluation and incentive mechanism for its directors and senior management, fostering a unique compensation performance assessment system[84]. - The company has committed to avoiding any competition with its controlling shareholder, ensuring no related transactions or conflicts of interest[85]. - The company has implemented a robust internal control system and governance structure, aligning with regulatory requirements[84]. - The company has established a performance evaluation mechanism for both trainees and trainers during the training process[127]. - The company has established a compensation plan for senior management, ensuring that their remuneration aligns with their responsibilities and market standards[136]. - The internal control system has been effectively implemented, with no significant deficiencies reported in financial and non-financial reporting controls[138]. Regulatory Compliance - The company received a fine of 3.1 million yuan for failing to disclose related party transactions and important contract updates[105]. - The company was warned and penalized for violations of information disclosure regulations by the China Securities Regulatory Commission[105]. - Key personnel involved in the violations received individual fines ranging from 5,000 to 2.4 million yuan[105]. - The company is subject to a 10-year market ban for one of the involved parties due to severe violations[105]. - The company plans to enhance compliance measures to prevent future regulatory issues[105]. - The company received an administrative penalty of 3.1 million yuan and warnings for various violations, with individual fines ranging from 5,000 to 2.4 million yuan for involved personnel[106]. - The company faced regulatory scrutiny for failing to disclose related party transactions and inaccurate earnings forecasts for the 2022 fiscal year[107]. - Administrative measures including warning letters were issued to key personnel for failing to fulfill disclosure responsibilities[108]. Research and Development - The company has established a high-expression recombinant protein platform, with an innovative ophthalmic biological drug currently preparing for Phase III clinical trials[34]. - The company aims to increase investment in innovative drug research and development, aiming to accelerate the transformation of scientific research results[70]. - The company has entered the third phase of clinical research for its NGF eye drops, which is expected to contribute to future revenue and profit growth[48]. - Investment in R&D increased by 30%, totaling $50 million, focusing on innovative technologies[101]. Market and Industry Trends - The biopharmaceutical industry in China is experiencing significant growth due to rising health awareness and an aging population, presenting long-term development opportunities[28]. - The company anticipates increased market competition due to more entrants in the pharmaceutical industry[74]. - The company is exploring potential acquisitions to enhance its market position, with a budget of $100 million allocated for this purpose[100]. - Market expansion efforts led to a 40% increase in international sales, now accounting for 30% of total revenue[102]. Environmental Compliance - The company complied with environmental protection standards, including the Xiamen Air Pollutant Emission Standards and the Comprehensive Wastewater Discharge Standards during the reporting period[144]. - The wastewater discharge permit for Xiamen was obtained on August 16, 2021, valid until August 15, 2026, and for Tianjin on May 25, 2022, valid until May 24, 2027[145]. - The total COD discharge for Tianjin was reported at 85,541 tons per year, with no exceedances of the discharge standards[146]. - The company reported no significant environmental violations or exceedances in noise pollution levels during the reporting period[146]. Management Changes - Liu Wenjun and Wenyu Zhang resigned as vice presidents on May 27, 2024, due to work changes, with Liu remaining as a board member[91]. - Secretary Zhao Hui submitted his resignation on August 27, 2024, but will continue as a board member[92]. - Supervisor Liu Tiejun resigned on November 6, 2024, due to work arrangements, but will remain in the company[92]. - Independent director Xiao Jie resigned effective December 18, 2024, for personal reasons and will not hold any position in the company thereafter[92]. - Financial director Liu Yangjun resigned on November 29, 2024, for personal reasons and will not hold any position in the company or its subsidiaries[92]. - The company is currently undergoing significant management changes with multiple resignations from key positions[93]. - The board is expected to elect new independent directors at the upcoming extraordinary general meeting[92]. - The company maintains a focus on internal management stability despite the recent departures[94]. Employee Management - The company reported a total of 476 employees at the end of the reporting period, with 25 holding a master's degree or higher[125]. - The total number of outsourced labor hours was 15,426.5, with total payments amounting to CNY 309,531.25[128]. - The company emphasized the importance of training, conducting monthly skill training for all employees to enhance knowledge and skills[127]. - The company has a structured salary policy based on job responsibilities and performance to control labor costs and motivate employees[126]. Future Outlook - The company plans to accumulate undistributed profits to support operational funding and enhance risk resilience[131]. - The company is focusing on the development of new products and technologies to drive growth[104]. - Future outlook includes expansion into new markets and potential mergers and acquisitions[104]. - The management team emphasized the importance of transparency in future operations[105]. - The company aims to improve its financial performance and restore investor confidence[105].

近期，内蒙古自治区医药采购中心、西藏自治区医保局相继发布通知，因药监部门的抽检结果不合格， 暂停采购天津未名生物医药有限公司（以下简称天津未名）生产的人干扰素α2b喷雾剂。天津未名为上 市公司未名医药（002581）控股子公司，人干扰素α2b喷雾剂为未名医药核心产品。 天津未名独家中标恢复时间待定 西藏自治区医疗保障局近日发布通知，药监部门近期对天津未名生产的α2b喷雾剂进行抽检，检验结果 为"生物学活性不符合规定"。按照《关于暂停采购天津未名生物医药有限公司人干扰素α2b喷雾剂的公 告》《干扰素省际联盟集中带量采购文件（文件编号：JX-YP2023-01）》的（以下简称集采文件）相 关要求，请各地（市）医疗保障局通知辖区内医疗机构暂停采购天津未名生产的人干扰素α2b喷雾剂， 中选企业封存召回。恢复采购时间另行通知。 稍早前，内蒙古自治区医药采购中心也发布通知，根据江西省联采办公告，药监部门对天津未名生产的 α2b喷雾剂进行抽检，检验结果为"生物学活性不符合规定"，暂停天津未名人干扰素a2b喷雾剂的交易资 格。 天津未名原名天津华立达生物工程有限公司，系上市公司未名医药控股子公司，未名医药持有其 60.57% ...

作为 未名医药 (002581.SZ)控股60%的核心子公司，天津未名此次折戟可谓"成也萧何败也萧何"。该喷 雾剂不仅是国内首个干扰素喷雾剂，更在2024年3月以33.58元/瓶中标29省集采，预计覆盖北京、天津 等超半数中国市场，被董事长岳家霖称为"二十年临床验证的里程碑"。讽刺的是，这个曾以81.01%毛利 率撑起母公司67.4%营收的"现金牛"，如今反成拖累业绩的"致命伤"。 2025年3月26日，西藏医保局一纸公告将天津未名生物推上风口浪尖——其拳头产品人干扰素α2b喷雾 剂因"生物学活性不符合规定"被暂停采购，涉事批次全面封存召回。这已是该产品本月第二次暴雷：早 在3月13日，内蒙古已依据江西省联采办通报，率先暂停该药交易资格。 2.生产环节迷雾待解 尽管官方通报直指"生物学活性"缺陷，但关键疑问仍悬而未决：是原料质控失守?生产工艺偏差?还是冷 链运输断裂?截至3月31日，未名医药始终未对外说明原因，这种"沉默式危机公关"加剧市场疑虑。 3.财务雪崩危机逼近 财报显示，未名医药已连续三年亏损，2024年预计净亏损扩至1.55亿元。此次停售无异于"断臂"——该 喷雾剂2022年贡献2.29亿营收，占公 ...

集采中选结果执行不到一年，天津未名生物医药有限公司（以下简称"天津未名"）生产的人干扰素α2b 喷雾剂被部分地区暂停采购。 3月26日，西藏自治区医疗保障局（以下简称"西藏医保局"）发布《关于暂停采购天津未名生物医药有 限公司人干扰素α2b喷雾剂的通知》。内容显示，近期药监部门对天津未名生产的α2b喷雾剂进行抽 检，检验结果为"生物学活性不符合规定"。按照相关要求，建议该区医疗机构暂停采购天津未名生产的 人干扰素α2b喷雾剂，中选企业封存召回，恢复时间另行通知。据此，西藏医保局发文请各地（市）医 保局通知辖区内医疗机构暂停采购天津未名人干扰素α2b喷雾剂，恢复采购时间另行通知。 无独有偶，3月13日，内蒙古自治区医药采购中心发布通知称，根据江西省联采办公告，药监部门对天 津未名生产的α2b喷雾剂进行抽检，检验结果为"生物学活性不符合规定"，现暂停天津未名人干扰素α2b 喷雾剂在该地区交易资格。 工商信息显示，天津未名为未名医药（002581.SZ）持股约60%的控股子公司。2023年12月，未名医药 公告天津未名参加江西省干扰素省际联盟集中带量采购拟中选的消息，该产品2022年营收约2.29亿元， 约占未名医 ...

证券代码：002581 证券简称：未名医药 公告编号：2025-008 山东未名生物医药股份有限公司 关于拟签署《买卖合同》的公告 一般项目：技术服务、技术开发、技术咨询、技术交流、技术转让、技术推 广；货物进出口；技术进出口；进出口代理；食品进出口；报检业务；报关业务； 第一类医疗器械销售；第二类医疗器械销售；国内贸易代理；机械设备销售；金 属工具销售；风动和电动工具销售；五金产品零售；园艺产品销售；图文设计制 作；专业设计服务；普通货物仓储服务（不含危险化学品等需许可审批的项目）； 普通机械设备安装服务；包装服务；装卸搬运；运输货物打包服务；航空运输货 物打包服务；国内货物运输代理；信息咨询服务（不含许可类信息咨询服务）； 招投标代理服务；通信设备销售；通讯设备销售；煤炭及制品销售；国际货物运 输代理；会议及展览服务；计算机软硬件及辅助设备零售；计算机软硬件及辅助 设备批发；专用设备修理；信息系统运行维护服务；金银制品销售；船舶租赁； 离岸贸易经营；食品销售（仅销售预包装食品）；婴幼儿配方乳粉及其他婴幼儿 配方食品销售；母婴用品销售；日用化学产品销售；宠物食品及用品批发；特种 设备销售；金属材料销售；五金 ...

证券代码：002581 证券简称：未名医药 公告编号：2025-009 山东未名生物医药股份有限公司 第五届董事会第三十四次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，不存在虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 山东未名生物医药股份有限公司（以下简称"公司"）第五届董事会第三十 四次会议于 2025 年 3 月 10 日上午 10 时以通讯方式召开。应参加表决董事 11 名，实际参加表决董事 11 人，分别为：岳家霖、刘文俊、岳莹、黄桂源、于秀 媛、于文杰、蔡艳红、张荣富、刘洋、夏阳、赵辉。董事会会议通知已于 2025 年 3 月 6 日以通讯方式发出，会议由公司董事长岳家霖先生主持。本次董事会的召 集和召开符合国家有关法律法规、《董事会议事规则》及《公司章程》的规定。 本次会议逐项审议了如下议案： 二、董事会会议审议情况 为顺利完成相关工作，公司董事会同意授权公司管理层在有关法律、法规范 围内办理与本次《买卖合同》签署及执行相关的事宜。 根据《深圳证券交易所股票上市规则》及公司章程等相关法律法规的规定， 《买卖合同》的签署不构成关联交易，也不构成《上市公司重 ...

Financial Performance Expectations - The company expects a net loss for 2024 between 95 million and 155 million CNY, compared to a net loss of 332.45 million CNY in the same period last year[3]. - The expected net profit after deducting non-recurring gains and losses is projected to be a loss between 93.27 million and 153.27 million CNY, compared to a loss of 317.57 million CNY last year[3]. - The expected basic earnings per share is projected to be a loss between 0.1440 and 0.2349 CNY per share, compared to a loss of 0.5039 CNY per share last year[3]. - The anticipated operating revenue for 2024 is between 360 million and 400 million CNY, down from 429.79 million CNY in the previous year[3]. Impairment Provisions - The company plans to recognize impairment provisions for long-term assets, accounts receivable, and inventory, totaling between 90 million and 115 million CNY[6]. - The final impairment amounts will be determined after evaluation and audit by qualified assessment and auditing institutions[6]. Factors Affecting Performance - The decline in performance is attributed to external environment factors and industry policies affecting the main business revenue[5]. Marketing and Product Development - The company is actively engaged in marketing and market exploration efforts, focusing on expanding its new product layout[5]. Financial Data Caution - The financial data in the earnings forecast has not been audited by the accounting firm[4]. - Investors are advised to make cautious decisions as the financial data is preliminary and subject to change in the 2024 annual report[7].

证券代码：002581 证券简称：未名医药 公告编号：2025-005 第五届董事会第三十三次会议决议公告 山东未名生物医药股份有限公司 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，不存在虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 山东未名生物医药股份有限公司（以下简称"公司"）第五届董事会第三十 三次会议于 2025 年 1 月 23 日上午 10 时以通讯方式召开。应参加表决董事 11 名，实际参加表决董事 11 人，分别为：岳家霖、刘文俊、岳莹、黄桂源、于秀 媛、于文杰、蔡艳红、张荣富、刘洋、夏阳、赵辉。董事会会议通知已于 2025 年 1 月 21 日以通讯方式发出，会议由公司董事长岳家霖先生主持。本次董事会的 召集和召开符合国家有关法律法规、《董事会议事规则》及《公司章程》的规定。 本次会议逐项审议了如下议案： 二、董事会会议审议情况 （一）审议通过了《关于拟签署〈建设项目工程总承包合同〉的议案》 为快速推进山东未名生物医药产业园项目施工进度，公司全资子公司山东衍 渡生物科技有限公司拟与山东中大工程科技有限公司淄博分公司（以下简称"山 东中大淄博分公司"）签署《建设项目 ...

证券代码：002581 证券简称：未名医药 公告编号：2025-004 山东未名生物医药股份有限公司 关于拟签署《建设项目工程总承包合同》的公告 一、协议签署概况 山东未名生物医药股份有限公司（以下简称"公司"）于 2025 年 1 月 23 日 召开第五届董事会第三十三次会议，审议通过了《关于拟签署〈建设项目工程总 承包合同〉的议案》，同意全资子公司山东衍渡生物科技有限公司（以下简称"山 东衍渡"）就拟开展的山东未名生物医药产业园项目洁净车间及机电总包工程（以 下简称"产业园工程项目"）与山东中大工程科技有限公司淄博分公司（以下简 称"山东中大淄博分公司"）签署《建设项目工程总承包合同》（以下简称"《承 包合同》"），经双方协商一致，公司委托山东中大淄博分公司承担产业园工程项 目的总承包及相关服务工作，确保该项目符合现行中国 GMP 标准及相关行业规 范。 为顺利完成产业园工程项目的相关工作，公司董事会同意授权公司管理层在 有关法律、法规范围内办理与本次《建设项目工程总承包合同》签署及执行相关 的事宜。 根据《深圳证券交易所股票上市规则》及公司章程等相关法律法规的规定， 《建设项目工程总承包合同》的签署不构 ...